Bioporto: Nuværende formand trækker sig og ny søges
Selskabet udsendte en pressemeddelelse i går at den nuværende formand John McDonough ønsker at stoppe senest ved næste generalforsamling i foråret 2025. Samtidig indeholder meddelelsen interessant information om hvilken kandidat de leder efter. Profilen skal blandt andet have fokus på de lokale investorer og kunne interagere dybere med dem samt fortsætte selskabets vækstrejse.
Læs hele meddelelsen her: Bioporto PM
Disclaimer: HC Andersen Capital modtager betaling fra Bioporto for en Digital IR/Corporate Visibility abonnementsaftale. Analytiker Claus Thestrup 8:15 AM, 17.12.2024
BioPorto
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.
Read more on company page